NCT00735501已完成不适用
Safety of Levemir® (Insulin Detemir) Treatment in Patients With Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 314
- 主要终点
- Incidence of serious adverse drug reactions, including major hypoglycaemic events
研究概览
简要总结
This observational study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in subjects with type 2 diabetes during Levemir® treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Any patient with type 2 diabetes
- •Currently treated with basal human insulin therapy (basal only or in combination with oral glucose lowering drugs or other insulin)
- •Selection of patients will be at the discretion of the treating physician after the decision to prescribe one of the study products to the patient
排除标准
- •Known or suspected allergy to study product(s) or related products.
- •Pregnancy or breastfeeding or intention of becoming pregnant within the next 6 months
研究组 & 干预措施
A
干预措施: insulin detemir (Drug)
结局指标
主要结局
Incidence of serious adverse drug reactions, including major hypoglycaemic events
时间窗: After 26 weeks
次要结局
- Weight changes(at 12 and 26 weeks)
- HbA1c(at 12 and 26 weeks)
- Number of all adverse drug reactions(after 12 and 26 weeks)
- Number of all hypoglycaemic events(at 12 weeks and 26 weeks)
- Variability in fasting plasma glucose (FPG) values and average FPG levels at visits(at 12 and 26 weeks)
研究者
相似试验
已完成
不适用
Observational Study to Observe the Safety of Levemir® Treatment in Children and Adolescents With Type 1 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00704574Novo Nordisk A/S159
已完成
3 期
Safety and Efficacy of Insulin Detemir in Combination With OAD in Type 2 DiabetesDiabetesDiabetes Mellitus, Type 2NCT00604396Novo Nordisk A/S477
已完成
3 期
Efficacy and Safety of Insulin Detemir in Type 1 DiabetesDiabetesDiabetes Mellitus, Type 1NCT00595374Novo Nordisk A/S114
已完成
不适用
Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 DiabetesDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT01542463Novo Nordisk A/S4,464
已完成
不适用
Observational Study of Patients With Diabetes Using Levemir® FlexPen®DiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2NCT00670683Novo Nordisk A/S797